A. Patterson

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).

A. Harris, A. Patterson, H. Barham, 1995, British Journal of Cancer.

Novel chimeric gene promoters responsive to hypoxia and ionizing radiation

A. Patterson, B. Marples, K. Williams, 2002, Gene Therapy.

Can gene therapy overcome the problem of hypoxia in radiotherapy?

A. Patterson, G. Dachs, O. Greco, 2000, Journal of radiation research.

Enzymology of tirapazamine metabolism: a review.

A. Patterson, E. Chinje, I. Stratford, 1998, Anti-cancer drug design.

The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions.

A. Harris, A. Patterson, I. Stratford, 2000, Biochemical pharmacology.

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

A. Harris, A. Patterson, E. Chinje, 1999, British Journal of Cancer.

Using gene therapy to determine the mechanism of hypoxic activation of tirapazamine.

A. Patterson, E. Chinje, I. Stratford, 1998 .

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

A. Harris, A. Patterson, E. Chinje, 2000, British Journal of Cancer.

The role of DT-diaphorase in determining the sensitivity of human tumor cells to tirapazamine (SR 4233).

A. Harris, A. Patterson, G. Adams, 1994, International journal of radiation oncology, biology, physics.